OncoLink Cancer Treatment and Resources

Lung Cancer Mortality in the Mayo Lung Project: Impact of Extended Follow-up

Pamela M. Marcus, Erik J. Bergstralh, Richard M. Fagerstrom, et al.
Abramson Cancer Center of the University of Pennsylvania
Last Modified: November 1, 2001

Reviewers: Li Liu, MD
Source: Journal of the National Cancer Institute, Volume 92:1308-1316, (August) 2000

Précis: Screening does not reduce long-term lung cancer mortality

Introduction

At present, there is widespread acceptance that screening for the early detection of lung cancer is not indicated. The American Cancer Society and the National Cancer Institute (NCI) recommend against efforts for early detection of lung cancer by mass screening (Ann Intern Med 1989 Aug 1;111(3):232-7). An early report of the Mayo Lung Project observed no reduction in lung cancer mortality with an intense screening regimen consisting of chest x-ray and sputum cytology. In this report, the researchers updated their results with extended follow-up and more participants.

Method

A total of 9211 male smokers were randomly assigned to either undergo a chest x-ray and sputum cytology every 4 months for 6 years (screening group) or were advised to have the same tests annually (usual care group).

Results

  • Lung cancer mortality was 4.4 per 1000 person-years in the screening group and 3.9 per 1000 person-years in the usual-care group, which was not statistically different.
  • The median survival after diagnosis for the screened group was 1.3 years compared with 0.9 years for those in the usual-care group.
  • For those with resected early-stage disease, the median survival was 16 years in the screened group compared with 5 years in the usual-care group, although this was not statistically significant.

Discussion

After an extended follow-up, the researchers of the Mayo Lung Project concluded that intense screening of smokers by chest x-ray and sputum cytology did not reduce the lung cancer mortality rate, but did appear to increase survival length. This study suggests that such screening may be identifying lung cancers earlier, but with limited clinical relevance.

OncoLink I wish u knew...

Dr. Rebbeck talks about the role of cancer biology and genetics in cancer research and applying that to clinical care. Read more.

Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet

Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy

Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies

Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer

Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults

OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews


Ask the Experts
Brown Bag Chat
Tracy's Corner

About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement

OncoLink Cancer Resources RSS What's New RSS